Onkologie. 2024:18(3):220-222 | DOI: 10.36290/xon.2024.042
Pembrolizumab in the treatment of non-small-cell lung cancer with renal metastases
- Komplexní onkologické centrum Pardubického kraje, Pardubice
Non-small cell lung cancer (NSCLC) has shown a decline in incidence and mortality in the Czech Republic. However, over half of new cases are still diagnosed at the stage four. The renal parenchyma is rare metastatic site. Renal metastases are often asymptomatic and typically an incidental finding on imaging studies. This case report focuses on a patient with NSCLC and renal metastases treated with pembrolizumab. The efficacy of pembrolizumab has been confirmed in the KEYNOTE-024 trial in patients with NSCLC and high PD-L1 (programmed death-ligand 1) expression. Pembrolizumab has been available for this indication in the Czech Republic since 2019. This case underscores the significant role of immunotherapy in the treatment of NSCLC and emphasizes the importance of a multidisciplinary approach to treatment and monitoring of immunotherapy-related side effects.
Keywords: NSCLC, pembrolizumab, PD-L1, renal metastases.
Accepted: June 18, 2024; Published: June 24, 2024 Show citation
References
- SVOD. [Internet]. Available from: https://svod.cz/.
- Scatena C, Comin CE, Lapini A, et al. Renal metastasis from pulmonary adenocarcinoma: the pathologist's approach to an uncommon finding: case report and review of the literature. Appl Immunohistochem Mol Morphol. 2013;21(5):460-463. doi: 10.1097/PAI.0b013e31827101b1. PMID: 23060303.
Go to original source... 
Go to PubMed... - Wang J, Wang L, Long L, et al. Solitary renal metastasis from squamous cell carcinoma of the lung: a case report. Medicine (Baltimore). 2019;98(5):e14310. doi: 10.1097/MD. 0000000000014310. PMID: 30702606; PMCID: PMC6380867. Go to original source... Go to PubMed...
- Zhou C, Urbauer DL, Fellman BM, et al. Metastases to the kidney: a comprehensive analysis of 151 patients from a tertiary referral centre. BJU Int. 2016;117(5):775-782. doi: 10.1111/bju.13194. Epub 2015 Jul 5. PMID: 26053895; PMCID: PMC4670601. Go to original source... Go to PubMed...
- Flynn JP. Gerriets V. Pembrolizumab. 2019. Available from: https://www.ncbi.nlm.nih.gov/books/NBK546616/#article-58888.s3.
- Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016;375(19):1823-1833. doi: 10.1056/NEJMoa1606774. Epub 2016 Oct 8. PMID: 27718847. Go to original source... Go to PubMed...
- Reck M, Rodríguez-Abreu D, Robinson AG, et al. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. J Clin Oncol. 2019;37(7):537-546. doi: 10.1200/JCO.18.00149. Epub 2019 Jan 8. PMID: 30620668. Go to original source... Go to PubMed...
- Romão R, Mendes AS, Ranchor R, et al. Impact of Immune-Related Adverse Events on Immune Checkpoint Inhibitors Treated Cancer Patients' Survival: Single Center Experience and Literature Review. Cancers (Basel). 2023;15(3):888. doi: 10.3390/cancers15030888. PMID: 36765845; PMCID: PMC9913676. Go to original source... Go to PubMed...
- Pagkopoulou E, Simopoulou T, Maragkouli E, et al. Arthritis and Myositis in a Patient Treated with Programmed Cell Death-1 (PD-1) Inhibitor Pembrolizumab for Lung Cancer. Mediterr J Rheumatol. 2020;31(3):355-357. doi: 10.31138/mjr.31.3.355. PMID: 33163870; PMCID: PMC7641028. Go to original source... Go to PubMed...